Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew P Goetz

Showing results (81-90 of 265) with videos related to

Pageof 27
Sort By:
Clinical & Experimental Metastasis|February 16, 2013
Matrix detachment and proteasomal inhibitors diminish Sulf-2 expression in breast cancer cell lines and mouse xenograftsAshwani Khurana, Deok Jung-Beom, Xiaoping He, et al.
Breast Cancer Research : BCR|March 12, 2011
Estrogen receptor-beta sensitizes breast cancer cells to the anti-estrogenic actions of endoxifenXianglin Wu, Malayannan Subramaniam, Sarah B Grygo, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|February 18, 2022
Clinical pharmacogenomic testing and reporting: A technical standard of the American College of Medical Genetics and Genomics (ACMG)Marwan K Tayeh, Andrea Gaedigk, Matthew P Goetz, et al.
Molecular Therapy Oncolytics|December 2, 2022
Oncolytic Urabe mumps virus: A promising virotherapy for triple-negative breast cancerMarshall D Behrens, Robert J Stiles, Gennett M Pike, et al.
Oncotarget|June 25, 2019
Spontaneous murine tumors in the development of patient-derived xenografts: a potential pitfallAnn M Moyer, Jia Yu, Jason P Sinnwell, et al.
Clinical Colorectal Cancer|August 8, 2007
Pemetrexed and oxaliplatin for metastatic colorectal cancer: results of a phase I Mayo Cancer Center Research Consortium trial, MC0248Steven R Alberts, George P Kim, Michelle R Mahoney, et al.
Breast Cancer Research and Treatment|January 4, 2021
Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trialsMatthew P Goetz, Meena Okera, Hans Wildiers, et al.
The Oncologist|June 15, 2020
Health-Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2- Advanced Breast CancerMatthew P Goetz, Miguel Martin, Eriko Tokunaga, et al.
Breast Cancer Research : BCR|August 24, 2021
Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trialPatrick Neven, Hope S Rugo, Sara M Tolaney, et al.
NPJ Breast Cancer|December 28, 2018
Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacyAngelo Di Leo, Joyce O'Shaughnessy, George W Sledge, et al.
Pageof 27

Showing results (81-90 of 265) with videos related to

Sort By:
Pageof 27
Clinical & Experimental Metastasis|February 16, 2013
Matrix detachment and proteasomal inhibitors diminish Sulf-2 expression in breast cancer cell lines and mouse xenograftsAshwani Khurana, Deok Jung-Beom, Xiaoping He, et al.
Breast Cancer Research : BCR|March 12, 2011
Estrogen receptor-beta sensitizes breast cancer cells to the anti-estrogenic actions of endoxifenXianglin Wu, Malayannan Subramaniam, Sarah B Grygo, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|February 18, 2022
Clinical pharmacogenomic testing and reporting: A technical standard of the American College of Medical Genetics and Genomics (ACMG)Marwan K Tayeh, Andrea Gaedigk, Matthew P Goetz, et al.
Molecular Therapy Oncolytics|December 2, 2022
Oncolytic Urabe mumps virus: A promising virotherapy for triple-negative breast cancerMarshall D Behrens, Robert J Stiles, Gennett M Pike, et al.
Oncotarget|June 25, 2019
Spontaneous murine tumors in the development of patient-derived xenografts: a potential pitfallAnn M Moyer, Jia Yu, Jason P Sinnwell, et al.
Clinical Colorectal Cancer|August 8, 2007
Pemetrexed and oxaliplatin for metastatic colorectal cancer: results of a phase I Mayo Cancer Center Research Consortium trial, MC0248Steven R Alberts, George P Kim, Michelle R Mahoney, et al.
Breast Cancer Research and Treatment|January 4, 2021
Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trialsMatthew P Goetz, Meena Okera, Hans Wildiers, et al.
The Oncologist|June 15, 2020
Health-Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2- Advanced Breast CancerMatthew P Goetz, Miguel Martin, Eriko Tokunaga, et al.
Breast Cancer Research : BCR|August 24, 2021
Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trialPatrick Neven, Hope S Rugo, Sara M Tolaney, et al.
NPJ Breast Cancer|December 28, 2018
Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacyAngelo Di Leo, Joyce O'Shaughnessy, George W Sledge, et al.
Pageof 27